IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 5395 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (66 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed2182    
    Printed98    
    Emailed1    
    PDF Downloaded346    
    Comments [Add]    

Recommend this journal

 


 
LETTER TO THE EDITOR
Year : 2009  |  Volume : 41  |  Issue : 2  |  Page : 91-92
 

Can we prevent ondansetron induced fatal ventricular tachycardia?


Emcure Pharmaceuticals Ltd, Rajiv Gandhi IT Park Phase I, MIDC, Hinjwadi Pune - 411 057, India

Correspondence Address:
Onkar C Swami
Emcure Pharmaceuticals Ltd, Rajiv Gandhi IT Park Phase I, MIDC, Hinjwadi Pune - 411 057
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.51352

Rights and Permissions



How to cite this article:
Swami OC. Can we prevent ondansetron induced fatal ventricular tachycardia?. Indian J Pharmacol 2009;41:91-2

How to cite this URL:
Swami OC. Can we prevent ondansetron induced fatal ventricular tachycardia?. Indian J Pharmacol [serial online] 2009 [cited 2021 Jun 15];41:91-2. Available from: https://www.ijp-online.com/text.asp?2009/41/2/91/51352


Sir,

We have read with interest the article 'Ondansetron induced fatal ventricular tachycardia' by Chandrakala et al., published in the Indian Journal of Pharmacology, August 2008. We would like you to give us the opportunity to discuss some of our observations on the same.

Ondansetron is a racemic compound having one chiral centre. Racemic Ondansetron is a 50:50 mixture of two enantiomers, R-Ondansetron and S-Ondansetron. In one animal study (in dogs), effects of R-Ondansetron, S-Ondansetron and racemic Ondansetron on cardiac arrhythmias (cardiotoxicity) were evaluated. QTc interval was most prolonged among animals receiving S-Ondansetron and racemic Ondansetron and was shortest among animals receiving R-Ondansetron. Based on these results it was reported that R-Ondansetron has less cardiotoxicity than S-Ondansetron or racemic Ondansetron. [1]

Bodhankar et al. in 2006 studied the effect of racemic Ondansetron, R-Ondansetron and S-Ondansetron on QTc interval in electrocardiograms of rats. The Ondansetron and its enantiomers were administered IV in a dose of 3 mg/Kg and changes in QT and RR interval and heart rate were calculated. The results of this study showed that racemic Ondansetron and S-Ondansetron significantly prolonged QTc interval, while R-Ondansetron did not prolong QTc interval as compared to the vehicle treated group. They concluded that R-Ondansetron is safer on the heart. Authors reported that S-Ondansetron might have higher inhibitory effects on Bezold-Jarisch reflex and this might be the reason for QTc prolongation with S-Ondansetron and racemic Ondansetron. [2]

A multicentric, randomized, double-blind, parallel group, comparative study on efficacy and safety of R-Ondansetron 4mg versus racemic Ondansetron 8 mg in 240 Indian patients with nausea and vomiting concluded that R-Ondansetron 4mg BID was equally effective compared to racemic Ondansetron 8mg BID with a slightly better safety profile compared to racemic Ondansetron. [3] This suggests that the S-Ondansetron component can be omitted without loss of efficacy. Efficacy and safety of R-Ondansetron solution was also studied in 410 pediatric patients confirming R-Ondansetron solution is safe and effective in pediatric patients with nausea and vomiting. [4]

From the above discussion it is clear that R-Ondansetron 4mg alone is sufficient for its anti-emetic potential and is preferable without its counterpart - the S-isomer which can prolong the QTc. So switching from racemic Ondansetron to R-Ondansetron is a rational therapeutic approach. R-Ondansetron has been approved by the DCGI on 15 th April 2005 and is available as tablets (2mg/4mg), solution (1mg/ 5ml) and injection (1mg/ml).

 
  References Top

1.Rubin; Paul D, Barberich; Timothy J. Methods for treating apnea and apnea disorders using optically pure R (+) Ondansetron. US Patent no: 6,548,082, 2003.  Back to cited text no. 1    
2.Bodhankar SL, Thakurdesai PA, Maurya OP. Effects of (RS)-Ondansetron and its enantiomers on QTc interval in Rats. Pharmacologyonline 2006;3:153-58.  Back to cited text no. 2    
3.Shinde J, Mandora VP, Joshi PK, Erram SS. Efficacy and safety of R-Ondansetron 4 mg versus racemic Ondansetron 8 mg: Results of a randomized, double blind, multicentric clinical trial. Indian Med Gazette 2005;139:444-7.  Back to cited text no. 3    
4.Garud KL, Godbole S, Mankar S, Pathak S. Efficacy and safety of R(+)Ondansetron solution in the treatment of nausea and vomiting in children: Results of an open-label, non-comparative, prospective clinical study. Indian Med Gazette 2006;140:112-4.  Back to cited text no. 4    




 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow